NCT00183976终止2 期
A Pilot Phase II Study of Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 15
- 试验地点
- 2
研究概览
简要总结
This study is for patients who have been treated before and either the treatment did not work or the lymphoma has come back.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically documented B-cell non-Hodgkin's lymphoma [NHL] (diffuse mixed, diffuse or follicular large B-cell, immunoblastic), Burkitt or Burkitt-like lymphomas, and primary effusion lymphomas.
- •Seropositive for HIV by any approved test (prior documentation of HIV seropositivity is acceptable).
- •Failed or relapsed after at least 1 prior chemotherapy treatment (chemotx) regimen but could have had no more than 2 prior chemotx regimens with only one of them being an anthracycline-containing regimen. Prior treatment (tx) with rituximab allowed.
- •All stages of disease
- •Measurable or evaluable tumor
- •Greater than or equal to 18 years of age
- •Karnofsky performance status greater than 50%
- •Absolute granulocyte count (AGC) greater than 1.0; platelets greater than 75,000; hemoglobin (Hgb) greater than 8.0 (unless these parameters are abnormal secondary to lymphomatous involvement of marrow, or due to HIV-related thrombocytopenia).
- •Bilirubin less than 2.0 (unless elevated secondary to lymphomatous involvement of liver or biliary system or due to other HIV-related medications such as Crixivan).
- •Creatinine less than 2.5 or creatinine clearance greater than 60 ml/min
- •Multigated acquisition (MUGA) scan or 2D echocardiogram indicating left ventricular ejection fraction (LVEF) greater than or equal to 50% within 42 days prior to first dose of study drug.
- •Patients with central nervous system (CNS) involvement are eligible provided that systemic lymphomatous disease is also present.
- •Concurrent therapy for HIV with any licensed agent or an agent available on an expanded access program will be required.
- •Signed informed consent including Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization.
排除标准
- •Acute intercurrent infection that may interfere with planned protocol. Patients with mycobacterium avium are not excluded. Chronic therapy with potentially myelosuppressive agents is allowed provided that entry hematologic criteria are met.
- •Second active tumor. Patients with non-melanomatous skin cancer, in-situ cervical cancer, or Kaposi's sarcoma, not requiring systemic chemotherapy may be entered on study.
- •Primary CNS lymphoma.
- •Documented history of congestive heart failure (CHF), hemodynamically unstable arrhythmia, myocardial infarction (MI) in the preceding 6 months, or evidence on electrocardiogram (EKG) of untreated cardiac ischemia.
- •Prior exposure to a liposomal anthracycline (liposomal doxorubicin or daunorubicin) for the treatment of lymphoma. Prior exposure to conventional doxorubicin allowed.
- •Prior radiation therapy within 4 weeks, unless for emergency conditions secondary to lymphoma (i.e., CNS tumor, cord compression)
- •Prior systemic chemotherapy or biologic therapy within 3 weeks
- •History of hypersensitivity reaction to anthracyclines or granulocyte colony-stimulating factor (G-CSF)
- •History of hypersensitivity reactions attributed to a conventional formulation of doxorubicin hydrochloride (HCl)
- •Investigational agent(s) within 4 weeks of start of study therapy.
- •History of cardiac disease with New York Heart Association (NYHA) greater than or equal to Class II, or clinical evidence of CHF
- •Pregnant or nursing mothers.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple MyelomaMultiple MyelomaNCT01160484Oncotherapeutics40
Unknown
2 期
Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung CancerNon-small Cell Lung CancerNCT01051362The First Affiliated Hospital of Guangzhou Medical University48
Unknown
2 期
Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast CancerHER2-positive Breast CancerNCT03933319Chinese Academy of Medical Sciences30
Unknown
2 期
A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer PatientsBreast CancerNCT01210768TTY Biopharm254
Unknown
2 期
Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast CancerMetastatic Breast CancerNCT01451580TTY Biopharm47